Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Muscimol SCHEMBL5781030 | 0.85 | NOTUM (0.47) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| Muscimol SCHEMBL352714 | 0.83 | — | — | |
| Muscimol SCHEMBL8680242 | 0.83 | NOTUM (0.46) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 | |
| Muscimol SCHEMBL7440548 | 0.83 | — | — | |
| Hymexazol SCHEMBL7571556 | 0.77 | NPC1 (0.42) | CYP2C19FFAR3RAB9AMEN1KMT2A | |
| SCHEMBL7423467 | 0.76 | VHL (0.38) | NOTUMPPARAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8299663 | 0.73 | — | — | |
| SCHEMBL595476 | 0.73 | PPARA (0.45) | CYP2C19PPARARAB9AMEN1KMT2A | |
| Propionic Acid SCHEMBL22518251 | 0.72 | PPARA (0.36) | PPARAFFAR3RAB9AMEN1KMT2A | |
| SCHEMBL9849314 | 0.72 | NOTUM (0.36) | NOTUMCYP2E1CYP2A6CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053080-B2 | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors | SCHERING CORPORATION (US) | 2006-05-30 | — | — | US | claimed |
| CN-111886005-B | Use of fluoroethyl normemantine for the prevention and treatment of anxiety | 瑞斯特医疗公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20220062378-A1 | METHODS OF TREATING OR INHIBITING ONSET OF HUNTINGTON'S DISEASE | UNIVERSITY OF COPENHAGEN (DK) | 2022-03-03 | — | — | US | disclosed |
| US-20210346469-A1 | Compositions and Methods for Increasing Insulin Sensitivity | NALPROPION PHARMACEUTICALS LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210198218-A1 | COMPOUNDS FOR THERAPEUTIC USE | DART NEUROSCIENCE LLC (US) | 2021-07-01 | — | — | US | disclosed |
| EP-3810184-A2 | METHODS OF TREATING OR INHIBITING ONSET OF HUNTINGTON'S DISEASE | University of Rochester (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10646166-B2 | Personal genome information environment providing device, personal genome information environment providing method, and computer program product | NATIONAL INSTITUTE OF JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2020-05-12 | — | — | US | disclosed |
| WO-2020037311-A1 | PROTEIN AND PEPTIDE BIOMARKERS FOR TRAUMATIC INJURY TO THE CENTRAL NERVOUS SYSTEM | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2020-02-20 | — | — | WO | disclosed |
| US-20190290618-A1 | Method for Treating Obesity | UNIV DUKE (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190262318-A1 | Method for Treating Obesity | NALPROPION PHARMACEUTICALS LLC | 2019-08-29 | — | — | US | disclosed |
| US-5521297-A | Nucleic acids encoding human metabotropic glutamate receptors | SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES (US) | 1996-05-28 | — | — | US | disclosed |
| EP-0701611-A1 | HUMAN METABOTROPIC GLUTAMATE RECEPTORS, NUCLEIC ACIDS ENCODING SAME AND USES THEREOF | SIBIA NEUROSCIENCES, INC. (US) | 1996-03-20 | — | — | EP | disclosed |
| US-5407935-A | 2,3-dihydro-6-nitro-7-sulfamoyl benzo(F)quinoxaline as alpha-amino 3-hydroxy-5-methyl-isoxazole propionic acid antagonist together with probenecid diuretics are useful for treating neurodegenerative diseases | WARNER-LAMBERT COMPANY (US) | 1995-04-18 | — | — | US | disclosed |
| WO-1995005600-A1 | METHODS OF DETECTING AND COMBATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | DUKE UNIVERSITY (US) | 1995-02-23 | — | — | WO | disclosed |
| WO-1994029449-A1 | HUMAN METABOTROPIC GLUTAMATE RECEPTORS, NUCLEIC ACIDS ENCODING SAME AND USES THEREOF | THE SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES, INC. (US) | 1994-12-22 | — | — | WO | disclosed |
| EP-0603301-A1 | PHARMACEUTICAL PREPARATION CONTAINING AN URICOSURIC AND AN EXCITATORY AMINO ACID ANTAGONIST | WARNER-LAMBERT COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| US-5284862-A | Neurodegenerative disorders including cerebrovascular disorders; antagonists for excitatory amino acid receptors | WARNER-LAMBERT COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
| WO-1993004688-A1 | PHARMACEUTICAL PREPARATION CONTAINING AN URICOSURIC AND AN EXCITATORY AMINO ACID ANTAGONIST | WARNER-LAMBERT COMPANY (US) | 1993-03-18 | — | — | WO | disclosed |
| WO-1992016205-A2 | NOVEL DERIVATIVES OF 2-CARBOXYNDOLES HAVING PHARMACEUTICAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 1992-10-01 | — | — | WO | disclosed |
| US-5145845-A | Substituted 2-carboxylindoles having pharmaceutical activity | WARNER-LAMBERT CO. (US) | 1992-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198218-A1 | COMPOUNDS FOR THERAPEUTIC USE | OPRK1, ACHE, OPRL1 | NOTUM 3998/4885CYP2E1 348/4885CYP2A6 1149/4885 |
| US-20190290618-A1 | Method for Treating Obesity | SLC6A2, COMT, GAP43 | NOTUM 375/4885CYP2E1 150/4885CYP2A6 151/4885 |
| US-20210346469-A1 | Compositions and Methods for Increasing Insulin Sensitivity | IAPP, GPR119, IRS1 | NOTUM 3411/4885CYP2E1 1474/4885CYP2A6 673/4885 |
| US-20190262318-A1 | Method for Treating Obesity | SLC6A2, COMT, GAP43 | NOTUM 375/4885CYP2E1 150/4885CYP2A6 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.